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Abstract: The objective of this paper was to review existing information regarding food 
effects on drug absorption within paediatric populations. Mechanisms that underpin  
food–drug interactions were examined to consider potential differences between adult and 
paediatric populations, to provide insights into how this may alter the pharmacokinetic 
profile in a child. Relevant literature was searched to retrieve information on food–drug 
interaction studies undertaken on: (i) paediatric oral drug formulations; and (ii) within 
paediatric populations. The applicability of existing methodology to predict food effects in 
adult populations was evaluated with respect to paediatric populations where clinical data 
was available. Several differences in physiology, anatomy and the composition of food 
consumed within a paediatric population are likely to lead to food–drug interactions that 
cannot be predicted based on adult studies. Existing methods to predict food effects cannot 
be directly extrapolated to allow predictions within paediatric populations. Development of 
systematic methods and guidelines is needed to address the general lack of information on 
examining food–drug interactions within paediatric populations. 
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1. Introduction 
Clinical studies that measure food–drug interactions are critical to evaluate appropriate dosing, 
timing, and formulation of new drug candidates. There are several excellent reviews on food effects in 
adult populations (e.g., [1]). 
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In paediatric populations there is evidence that a wide range of drugs are mixed with food prior to 
administration to ensure that medication is acceptable to the patient [2]. The British National 
Formulary for Children (BNF-C) [3] lists 11 drugs that are recommended to be mixed with food to 
assist with administration; specific foods mentioned include soft foods, yoghurt, apple sauce, jam or 
honey. The BNF-C also lists at least eight examples of medicines suggested to be mixed with fruit 
juice prior to administration [3]. 
The extrapolation of fed effects observed in adults into paediatric populations is an unexplored and 
complex area. There are key differences between the feeding patterns of paediatric patients and adults 
both in terms of food composition and feeding frequency. In addition, the gastrointestinal tract of 
paediatric patients can be different to that found in adults. This review seeks to highlight potential 
differences in fed effects in paediatric patients compared to adults by reviewing existing data sources 
on physiological/anatomical, physicochemical and formulation differences. 
2. Clinical Measurement of Food–Drug Interactions 
Clinically significant food–drug interactions are usually assessed in terms of peak plasma 
concentration (Cmax), time to Cmax (Tmax) and area under the absorption time curve (AUC) in a plot 
of plasma concentration against time. Differences in the rate of absorption (faster or slower) will alter 
Tmax yet are unlikely to affect Cmax or AUC. Differences in the extent of absorption will affect Cmax 
and AUC which typically have greater clinical significance compared to changes in Tmax. 
2.1. Regulatory Guidelines for Food–Drug Interaction Studies 
Food–drug interactions are widely reported in adult populations with regulatory bodies recognising 
their significance with dedicated guidance on the conduct of fed effect clinical studies [4]. In terms of 
regulatory guidance, a clinically significant food effect is defined as one where the 90 percent 
confidence interval fails to meet the limits of 80–125 percent for either Cmax or AUC of the fasted 
profile [4]. 
For paediatric populations the guidance surrounding food effects is limited. Based on US law, the 
“pediatric study decision tree” [5] allows extrapolation from adult data sets if there is sufficient 
similarity of both: (i) disease progression; and (ii) response to intervention between source and target 
population. If the exposure-response relationship of the medicinal product is assumed to be similar, the 
only PK studies required in paediatric populations, are those for dose determination and safety 
evaluation. This logic is also replicated in European Medicines Agency (EMA) guidance where it is 
stated that relative bioavailability comparisons of paediatric formulations with the adult oral 
formulation should typically be conducted in adults; with only dose selection pharmacokinetic studies 
required in paediatric populations [6]. This results in the majority of paediatric pharmacokinetic studies 
being conducted in the fasted state with very limited pharmacokinetic studies in the fed state. Indeed 
neither the EMA guideline on the role of pharmacokinetics in the development of medicinal products 
in the paediatric population nor the International Conference on Harmonisation (ICH) topic on clinical 
investigation of medicinal products in the paediatric population mention clinical studies to evaluate 
food effects in any capacity [7]. 
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3. Paediatric Diet and Composition of Food 
The composition of meals is subject to huge regional variation. The composition of a meal may not 
only affect the intestinal physiology, it can also affect the solubility of a drug. Typically a high fat 
meal will assist in the solubilisation of a poorly water soluble drug; this increased solubility provides a 
higher concentration gradient to drive absorption of a drug. For example, the bioavailability (in adults) 
of the poorly soluble drug atovaquone (log P 5.07) was unchanged by intake of two slices of toast, but 
increased 3- to 3.9-fold by further administration of 28 and 56 g of butter, respectively [8]. Similarly, 
the bioavailability (in adults) of griseofulvin (log P 1.9) was unchanged by intake of protein-rich or 
carbohydrate-rich, low-fat meals, but increased approximately seven times by intake of a lipid-rich meal 
[9]. However, Finkel et al. [10] reported that the absorption of penicillin V was reduced (in children) in 
the presence of food and also in an oily liquid compared to an aqueous liquid which suggests that the 
drug is preferentially sequestering within the fat and the overall absorption is reduced. 
The composition of meals in paediatric populations differs from that used in adults for many 
reasons, one is that nutritional needs and recommendations vary with age. Calories are consumed in 
the form of fat, carbohydrate and protein; fat accounts for approximately 50% of the energy in breast 
milk and is the main source of energy for infants less than six months old. As an infant matures the 
proportion of fat is gradually overtaken by carbohydrate as the chief energy source. In terms of unit 
weight the normal infant has much higher intake from fat and carbohydrate compared to an adult. 
3.1. Regulatory Advice on Meal Composition 
The type of food used within a clinical study to measure a food effect is detailed within regulatory 
guidance documents. The standardised FDA breakfast was proposed in 2002 [4] and describes a  
high-fat meal containing 50% to 65% of energy from lipids, 25% to 30% from carbohydrates, and 15% 
to 20% from proteins, with the meal providing a total of 800 to 1000 kcal. This FDA example high-fat 
test meal outlined in the guidance document was used to provide the greatest effects on gastro-
intestinal (GI) physiology as a lipid-rich meal will be retained longer in the stomach and more bile and 
pancreatic juice will be secreted so that systemic drug availability would be maximally affected. 
A possible composition of the meal would be two slices of toast with butter, two eggs fried in 
butter, two strips of bacon, 4 oz of hash brown potatoes, and 8 oz of whole milk. European guidance 
details a standardised high fat meal which is equivalent to the FDA breakfast; although a moderate 
meal is also listed as one that contains a total of 400–500 kcal of which approximately 150 kcal is fat 
[4]. 
EMA guidance highlights the relevance of the composition of the food used within a clinical study 
in terms of paediatric populations particularly for newborns and young infants where they are fed a 
predominantly (or exclusively) milk diet [4]. EMA ICH E11 guidance [6] states that for a medicinal 
product studied in paediatric patients extrinsic factors (e.g., diet) could impact on extrapolation of this 
data to other geographical regions (due to dietary differences). There has been a recent EMA concept 
paper on extrapolation of efficacy and safety in medicine development with reference to extrapolation 
of data from adults into paediatric populations and also across age subsets within the paediatric 
population, however there is no direct mention of extrapolation of food effects [11]. 
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Milk has a similar composition to a standard FDA breakfast with respect to the ratio of 
carbohydrate to fat to protein [12]. The meal used in paediatric populations varies due to the lack of 
regulatory guidance; in younger children milk is commonly used whereas a breakfast is used in older 
children. There is often debate about the relevance of the meal used in terms of mimicking a typical 
eating pattern in the relevant population. However, it is important that the meal used provides the 
maximum effect on gastrointestinal physiology aligned to the adult guidance; therefore a milk meal or 
portion size controlled FDA standard breakfast should form the meal of choice in such clinical studies. 
3.2. Paediatric Feeding Patterns 
Typical Western adult eating patterns are considered to comprise of three meals per day; although 
there is data to suggest that this is increasing with the total number of eating occasions being greater 
than 5 in over 60% of American adults [13]. If it is assumed that an adult sleeps for 8 h; the likely time 
interval between eating occasions is likely to be less than 4 h. A typical newborn will feed 
approximately 10 times daily [14], although this varies according to culture and global region. The 
pattern of eating occasions with age is shown in Figure 1 below. 
 
Figure 1. Influence of age on number of daily eating occasions within the United States of 
America (data extracted from [13]). 
Within the regulatory guidance for conducting food effect clinical studies, the standardised 
breakfast meal is to be ingested after an overnight fast of at least 10 h. The meal should be eaten in 
30 min or less, and at 30 min the drug product should be administered together with 240 mL of water. 
One hour after administration, water ad libitum is allowed and four hours post-dose food is allowed 
[4]. There is no similar guidance on the conduct of food effect studies in children although direct 
translation of this methodology to children younger than two years may lead to non-compliance both 
in terms of fasting periods and consumption of 240 mL water. It should also be noted that this practice 
is unlikely to represent typical habits in all populations in general practice. 
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3.3. Volume of Food Consumed 
The FDA standard breakfast is reported to have a volume of 513 mL, which is consistent with 
typical meal volumes in adults [15]. The volume of feed to give to neonates and young infants is 
typically calculated as 200 mL/kg/day; this equates to a volume of about 90 mL per feed for a term 
neonate (assuming a 3.5 kg baby fed eight times); up to 190 mL per feed for a six month old infant at 
7.6 kg. Functional gastric capacity has been estimated at 30 g/kg body weight; this equates to masses 
of 250, 285 and 345 g/meal for infants of average body weight at 7, 10 and 12–23 months respectively 
[16]. The relationship between functional gastric capacity and body weight is not valid for all weights 
as this would equate to a 75 kg adult requiring a meal of 2250 g, which is much greater than a typical 
meal. A recommended meal for a school child aged 5–7 has a total mass of 280 g, which assuming a 
density of close to 1 provides a volume estimate of 280 mL [17]. Therefore it can be assumed that the 
volume of food increases with age although the relationship is not easily described by a single study. 
The volume of food consumed per kilogram of bodyweight is higher in younger children; this is likely 
to be linked to the growth phase of the child. 
The amount of food that is necessary to initiate the fed state is not very well elucidated, however, 
administration of a small amount, 2 g, of long chain MAG to adults was observed to delay gastric 
emptying [18]. Therefore it is likely that there is greater alteration in gastric emptying in younger 
children where a greater proportion of the calorific intake is derived from fat. This suggests that 
volume is less critical than composition in terms of food–drug interactions within paediatric 
populations. 
4. Physiological and Anatomical Differences in Paediatric Populations that Affect  
Drug–Food Interactions 
Differences in gastrointestinal physiology and anatomy between paediatric and adult populations 
can significantly affect the rate of absorption and bioavailability of drugs. There are several excellent 
reviews that address this topic (e.g., [19]). This review considers these differences with a specific 
focus on food–drug interactions. 
4.1. Gastric Emptying 
Gastric emptying (GE) determines the onset of absorption as this is a rate-limiting step prior to drug 
exposure to the absorbing membrane of the small intestine. Many factors affect GE including meal 
volume and composition. The primary factor that dictates the emptying rate of the stomach is the 
calorific profile of the contents, but it is also influenced by other factors including volume, osmolality, 
viscosity, and temperature. Drugs where GE is known to be rate limiting include paracetamol [20]; 
busulfan [21]; ampicillin [22]; riboflavin [23] and levetiracetam [24]; differences in paediatric meal 
composition may therefore affect the pharmacokinetic profile of these drugs. There have also been 
several studies on gastric emptying of breast milk compared to formula and also the effect of fortifiers 
within breast milk; these show that breast milk empties faster than formula or cows’ milk [25] and that 
fortifiers do not alter rates of gastric emptying [26]. 
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4.1.1. Calorific Content and GE 
The caloric output from the stomach has been found to be between 2 and 4 kcal/min (8.4 and  
16.4 kJ/min) [1]. The fat content of a meal plays a critical role in determining the gastric emptying rate 
as fat contains twice as many calories as carbohydrate [27]. For example, administration of a lipid-rich 
meal with 200 mL of water resulted in a lag time of gastric emptying of 44 ± 20 min, compared with a 
lag time of 14 ± 11 min after intake of 200 mL water [28]. The higher the calorific content of the meal 
the longer the delay to GE and consequently delay to drug absorption. 
4.1.2. Volume and GE 
Gastric emptying of liquids is related to volume with increased volume showing rapid gastric 
emptying [29]. A separate study demonstrated that an increase in the volume of the solid component  
of a mixed solid/liquid meal results in more rapid gastric emptying of the solid but slower liquid 
emptying [30]. The reduced volume ingested by younger patients may not recreate the emptying rate 
anticipated by adult studies. 
4.1.3. Osmolality and GE 
Hexose sugars were previously shown to slow GE in an osmolality-dependent fashion [31]. 
However, more recent studies indicate that the slowing of GE is more likely to be dependent upon their 
specific molecular identity [32]. 
4.1.4. Viscosity and GE 
Gastric emptying time is linked to viscosity as solid particles take longer to empty compared to 
liquids, therefore a viscous meal shows a longer emptying time and thus a delayed Tmax [33]. 
Although neonates are fed predominantly liquid meals the introduction of soft, semi-solid foods occurs 
at around 4–6 months in Europe with a progression to more solid foods including bread and pasta at 
around 8–9 months of age [34]. The viscosity of food is likely to increase with age up to 
approximately two years and then be consistent through to adulthood; therefore GE may be faster than 
anticipated in children under two years of age. 
4.1.5. Temperature and GE 
There have been several studies conducted that examine the impact of temperature on GE that show 
conflicting results. Sun et al. (1988) reported that a liquid meal at body temperature was emptied from 
the stomach more rapidly that one either colder or warmer; this is of interest for neonates and infants 
who feed at approximately 37 °C [35]. However, Mishima et al., (2009) reported that a hot solid meal 
(60 °C) significantly accelerates gastric emptying compared to meals at 37 °C and 4 °C [36]. The 
temperature of food may need to be considered in relation to gastric emptying as well as for potential 
degradation on the drug product. 
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4.2. Gastrointestinal Transit Times 
The transit time within the small intestine is considered to be unaffected by food and estimated as  
3–4 h in adults [1]. However, food ingestion typically triggers distal intestine emptying therefore the 
timing of food in relation to medicines administration can be important. For example, when a  
non-disintegrating tablet was administered 45 min prior to a standard breakfast, the small intestinal 
transit time was reduced to approximately 100 min in those subjects where the tablet had already 
entered the small intestine before the breakfast was given [37]. This has particular relevance in the 
youngest patients where feeding is more frequent than in adults. 
4.3. Splanchnic Blood Flow 
Food intake induces an increased splanchnic blood flow, which in turn will increase the absorption 
and transfer of nutrients into the bloodstream. In terms of drug absorption increased splanchnic blood 
flow will increase the rate that the drug reaches the liver and may lead to alterations in the fraction of 
drug undergoing first pass metabolism. 
The effect of breast milk, adapted cow’s milk formula, and nucleotide supplemented cow’s milk 
formula on intestinal blood flow in neonates showed that there was no significant difference between 
the breast milk and adapted cow’s milk formula-fed groups; however, the nucleotide supplemented 
cow’s milk formula-fed group had significantly higher postprandial blood flow velocity and volume 
flow. A higher splanchnic blood flow may result in reduced bioavailability of a drug due to greater loss 
in first pass metabolism. 
4.4. Membrane Interactions 
Drug absorption involves transporters and enzymes which may not be fully mature in paediatric 
patients. However, the maturation patterns of these moieties are not well understood. Typically, it is 
reported that maturation follows that for functionality of the digestive system [38]. However, there is 
some evidence that the ontogeny is affected by feeding, where formula feeding appeared to accelerate 
maturation of caffeine and dextromethorphan metabolism by increasing the activity of CYP1A2 and 
CYP3A4, respectively compared to breast feeding [39]. Several plant-derived food and drink 
components have been shown to modulate enzymes and transporters in the intestine, leading to altered 
absorption of certain drugs. Commonly consumed fruit juices, teas, and alcoholic drinks contain 
phytochemicals that inhibit intestinal cytochrome P450 and phase II conjugation enzymes, as well as 
uptake and efflux transport proteins. Specific studies have shown that CYP 3A4 activity is reduced in 
the young and reach adult values during adolescence although the data is not conclusive [40]. 
Examples of foods that contain inhibitors of cytochrome P450 3A4 are grapefruit juice, garlic, and red 
wine [41]; these have predominantly been explored based on adult diets and there is limited 
information on paediatric food components. The difference in CYP3A4 expression coupled with 
consumption of different dietary components may have effects on drug–food interactions observed. 
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4.5. Review of Food Effects in Paediatric Populations 
Very few food effect studies have been conducted in paediatric patient populations; those reported 
in the literature are shown in Table 1. There is much more variability in the meal used to administer 
medicine doses to children which is most likely related to the lack of clear guidance in this area; the 
most common foods included milk or standardised breakfasts. 
The data in Table 1 show that in total there were 10 incidences where the pharmacokinetic 
parameters were unchanged in a paediatric population in the presence of food and 11 incidences where 
food led to a change in PK parameters. Where food altered the bioavailability of the drug the 
recommendations regarding concomitant administration with food made as a result of the study are 
included. Tmax was prolonged in many cases with Cmax and AUC being reduced more frequently 
than increased as a consequence of administration with food. The preceding sections of this review 
highlighted that for paediatric patients gastric emptying is likely to be slower in the presence of food, 
so the results are not surprising. The meals utilised when undertaking clinical fed effect studies in 
paediatric populations are also listed in Table 1. The meals varied in terms of composition, viscosity, 
volume and hydration such that the variability in composition may influence the results observed to a 
large extent. 
Of the 18 studies reported 11 showed the same pharmacokinetic result as that in adults in a food 
study; five showed different results to the adult study and two could not be compared. This difference 
in effects observed in adults compared to paediatric populations is a cause for concern as typically the 
effects of a food study are extrapolated from an adult population into a paediatric population. This 
presentation of the data emphasises the risks associated with this approach. 
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Table 1. Food effect studies conducted in paediatric populations. 




15 or 25 
mg/kg 
4 m–45 m (mean 
27 months) 
4oz milk or formula 
(Similac or Infamil) 
Cmax decreased at 15mg/kg dosing 
Cmax unchanged at 25 mg/kg 
dosing AUC unchanged all doses 
 [42] 
Adult study at 500mg dose 






15 or 25 
mg/kg 
4 m–45 m (mean 
27 months) 
4oz milk or formula 




Adult study at 500mg dose 
showed reduction in Cmax 









5 m–12 y 
Age-appropriate 
meal (volume and 
composition) 
Tmax prolonged  
Cmax unchanged 
Cefpodoxime can be 
administered without 
regard for food 
[44] 
Cmax and AUC eleveated 
in the fed states for all 
meals (high protein, low 










Cmax reduced (not significant) 
AUC increased (not significant) 
Concomitant 
administration of 




Absorption is delayed but 







mg/kg   
AUC unchanged  [48] 
The extent of absorption is 
relatively unaffected by the 














AUC and Cmax are reduced 
with food in adults (for the 
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Table 1. Cont. 
Drug Formulation Dose Age Range Meal Change in Parameter Comments Ref Comparable Adult Data Adult Ref 
Didanosine 
 
50 or 150 
mg/m2   
Cmax reduced 
AUC unchanged 
Take in the fasted state [52] 
AUC and Cmax are 
substantially reduced with 
some formulations if taken 
with food 
[53] 
Griseofulvin oral suspension 
10 or 15 
mg/kg/day 
19 m–11 y 
(mean 4.8 y) 
120 mL whole milk 
Cmax increased 
AUC increased 
Drug should be 
administered with whole 
milk or other food 














none; breast feeding; 
liquid (soup, broth); 
pancake; porridge or other 
Cmax increased (greater 
increased for crushed tablet) 
Pancake increased the 
exposure to a greater extent 
than milk 
Consumption of food at the 
time of dosing remains 
advisable 
[56] 
Cmax and AUC increased 




 75 mg/m2 
 
250 mL milk and 50 g 
biscuits 
Tmax prolonged 
Cmax significantly reduced 
 AUC significantly reduced 
6-MP should be taken in a 
fasting state to optimize 











4 year old 
child (n = 1) 
Milk or fruit squash 
In the presence of milk 
Cmax reduced 
AUC reduced 
Child required increased 
dose of mercaptopurine 
when taken with milk 
[60] 







Breakfast (milk or yogurt 




Insufficient data for a 
recommendation 
[61] 
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Table 1. Cont. 
Drug Formulation Dose 
Age 
Range 
Meal Change in Parameter Comments Ref Comparable Adult Data 
Adult 
Ref 
Methotrexate  15 mg/m2 
3–15 
years 
Milky meal = milk, 
cornflakes sugar, bread and 
butter Or citrus meal = 
orange juice, fresh orange, 
bread, butter and jam 
Milky meal: 
Tmax prolonged Cmax and 
AUC significantly reduced 
Citrus meal: Cmax and 
AUC unchanged 
Methotrexate absorption is 
delayed by food, particularly 
milk. For maximum absorption 
methotrexate should not be 
taken at meal times. 
[62] 













Cmax significantly reduced 
AUC significantly reduced 
Dosing Penicillin V with food 
will reduce its exposure 
[10] 
Slight alteration in 
pharmacokinetics such that it is 
recommended to dose penicillin 











Cmax reduced AUC 
reduced 
Dosing Penicillin V with milk 
will reduce its exposure 
[65] 
Slight alteration in 
pharmacokinetics such that it is 
recommended to dose penicillin 
V in the fasted state 
[64] 




Tmax prolonged Cmax 
reduced AUC variable 
Propylthiouracil administration 







products   
Standard breakfast of 
cornflakes, rye bread, 
butter, salami and low  
fat milk 
Effects dependent upon 
formulation 
 
Food effect is dependent upon 
formulation. Caution advised if 
switching brand. 
[68] 
Food has substantial but variable 
effects on absorption from 
modified-release formulations in 
adults. 
[69] 
6-thioguanine Not stated 40 mg/m2 
1–16 
years 
Standard breakfast of cereal 
with milk, toast and a glass 
of milk 
Tmax prolonged Cmax 
significantly reduced AUC 
significantly reduced 
Although there is a reduction in 
exposure with food there was 
no difference in 6-TGN 
concentrations after 4 weeks. 
Taking the drug on an empty 
stomach may not be necessary. 
[70] 
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The difference in food-effects between adult and paediatric populations is highlighted by a study on 
four different sustained-release theophylline formulations where the food effect was more marked in 
children compared to adults; the bioavailability in the fed state was reduced from 100% to 24% in 
children compared to a reduction to 67% in adults [68]. 
5. Physico-Chemical Food–Drug Interactions 
Classification of food–drug interactions aids in the prediction and prevention of their occurrence. 
Interactions between food and drug within the environmental matrix of the gastro-intestinal tract are 
usually physico-chemical rather than physiological or anatomical. These often relate to the formulation 
as well as the drug. The different composition of food consumed by paediatric populations may alter 
the incidence of this type of interaction. 
5.1. pH Effects 
The absorption of weak acids and bases changes in the presence of food due to the impact of food 
on the pH of the gastric environment. Typically weak bases can show reduced dissolution and 
therefore absorption in the presence of food due to the increased gastric pH (e.g., isoniazid [71] and 
indinavir [72]). Gastric pH in neonates is known to be somewhat higher than adult values therefore the 
presence of food may not further affect the absorption of weakly basic drugs. Conversely weak acids, 
including ibuprofen, have shown increased absorption in the presence of food which may also be 
attributed to a pH effect [73]. Typically a paediatric diet is likely to be of a similar pH to that of an 
adult; however additional caution is required when dosing with fruit juices which are known to have a 
low pH. 
The composition of food stuffs used to mix with drugs to aid administration also needs careful 
consideration for weakly acidic or basic drugs. Typically fruit juices are used or applesauce; these have 
pH values in the region of 3.3–4.1 [74]. Co-administration may therefore impede the absorption of 
weakly acidic drugs or enhance the absorption of weak bases. The stability of drugs co-mixed with 
food or drinks has previously been investigated (e.g., [75]). 
5.2. Viscosity 
A high viscosity within the intestinal lumen can reduce the diffusion rate of a drug and therefore 
reduce its overall absorption; this has previously been shown with bidisomide [76] in adults and with 
paracetamol, mefenamic acid, hydrochlorothiazide and cimetidine in dogs [77]. The composition of 
the meal is therefore paramount in understanding the viscosity within the gastro-intestinal lumen. 
In children younger than two years the overall absorption of certain drugs (e.g., bidisomide) may be 
increased due to the lower relative viscosity of the ingested food. 
5.3. Binding/Chelation 
Chelation or binding of drugs to components within the gastrointestinal lumen can reduce their 
absorption. For example, ciprofloxacin bioavailability is significantly reduced as a result of chelation 
in the presence of enteral nutrition formula [78]. Chelation to metal cations is the most widely  
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reported food interaction of this type that limits absorption with fluroquinolones, tetracyclines and 
some oral cephalosporins. 
Many cereals and fruit juices targeted at children are fortified with additional calcium, iron, 
magnesium and vitamins; this additional level of cations may enhance chelation and reduce bioavailability 
of drugs susceptible to chelation. The standard FDA breakfast contains 435 mg calcium, 4 mg iron,  
72 mg magnesium and 3.2 mg zinc; whereas a breakfast consisting of fortified cereal and calcium-fortified 
orange juice would contain approximately 1600 mg calcium [79]. This type of food interaction needs 
special consideration in paediatric populations. 
Milk, is a significant component of neonate and infants’ diets yet has been shown to reduce the 
absorption of many drugs including ketoprofen [80], mercaptopurine [60,81], methotrexate [62] and 
penicillin [65]. Proteins within food can also bind with drugs to reduce their exposure, for example 
phenytoin [82]. The composition of food in terms of protein and cations needs to be considered in the 
design of appropriate tests to predict food–drug interactions in children. 
5.4. Thermal Degradation 
Many drugs degrade at higher temperatures; the rate of degradation is proportional to the 
temperature as described by the Arrhenius equation. Exposure to high temperatures can also degrade 
other components of a medicine including taste masking excipients. Concomitant administration of 
drugs with hot drinks and hot meals is well known in adults. Although paediatric patients do not 
typically drink very hot liquids it is common to prepare formula milk with boiling water and to leave to 
stand to cool prior to administration. If a drug is added to a bottle at the same stage as the powdered 
formula, exposure to boiling water and high temperatures for the period of cooling (up to 30 min) 
could have an adverse effect on the stability of the drug and therefore on drug exposure to the patient. 
6. Formulation Influence on Food Effects 
Liquids are emptied from the stomach faster than solid food items, as the dimension of particles that 
can pass through the pylorus can limit gastric emptying. Tablet disintegration testing sets a particle 
size limit of 1.8–2.2 mm [83] as the relevant size to pass through the pyloric sphincter in adults as 
larger particles (>2 mm) require Phase III of the migrating motor complex (MMC) for ejection from 
the stomach [84]. The equivalent size is yet to be evaluated in children. When liquid medicines are 
administered in the presence of food their transit to the small intestine may be delayed and drug 
exposure profile altered compared to dosing in the fasted state [85]. The presence of food can also 
influence the disintegration of tablets due to the different mixing forces and consequently the time 
taken for sufficiently small tablet particles to transfer to the small intestine. Clinical studies have 
demonstrated a delay in absorption of drugs due to prolonged disintegration times in the fed state in 
dogs [86] and in man [87]. 
Formulation factors have previously been shown to affect onset of action and absorption and 
paediatric paracetamol suspensions have been designed to provide a rapid onset of action in both the 
fasted and fed state to reduce variability in pharmacokinetics [88]. The formulation used can affect the 
food effect observed therefore caution may be required when switching formulations in terms of 
instructions for administration with food. In paediatric patients where drugs are more frequently 
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administered as solutions, suspensions or extemporaneously crushed tablets this disintegration step has 
been removed; therefore the food effect may be different to that predicted from adult studies so extra 
vigilance is required. 
Milk-based formulations have been developed specifically to enhance the bioavailability of certain 
poorly soluble drugs [89]; these formulations have been shown to be stable and demonstrate that milk 
can be used as a component of the formulation as well independently to aid in drug 
administration [90]. 
 
6.1. Review of Food Effects in Paediatric Formulations 
Pharmacokinetic data and bioequivalence studies are typically conducted in adult populations for 
formulation changes, including the development of paediatric formulations. Table 2 details the existing 
published data on fed effect studies undertaken on formulations developed for paediatric use. 
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Table 2. Food effect studies on paediatric formulations conducted in adult populations. 
Drug Formulation Dose Food/Meal 
Timing of 
Dose 
Change in Parameter Remarks from Reference Reference 
Clobazam crushed tablet 20 mg Applesauce 
 
Cmax unchanged AUC 
unchanged 
Clobazam tablets can be given crushed with 
applesauce. Administration of clobazam with a 







1 tablespoon of yogurt or 1 
tablespoon Ensure® 
pudding or 1 tablespoon 
Cottage cheese 
overnight fast 
—3 h post 
dose 
Tmax prolonged  
(for cottage cheese) 
Cmax unchanged AUC 
unchanged 
The bioavailability when administered in 
yogurt, Ensure® pudding and cottage cheese, 
was similar to that of the intact capsule in these 







180mL orange juice 
without pulp or tomato 
juice; or soft food  
(1 tablespoon of  
strained pears) 
overnight fast 
—3 h post 
dose 
Tmax prolonged (for 
orange juice only) Cmax 
unchanged AUC 
unchanged 
The bioavailability when administered in orange 
juice, tomato juice, or a small amount of 
strained pears, was similar to that of the intact 
capsule in these healthy adult volunteers 
[93] 
Levetircetam crushed tablet 500 mg 
4oz applesauce 
120 mL enteral nutrition 
formula (Sustacal®) 
overnight fast 
—4 h post 
dose 
Cmax unchanged AUC 
unchanged 
The overall rate and extent of absorption was 
not significantly impaired after crushing and 
mixing of the tablet with either a food vehicle or 







1 level tablespoon 
applesauce (15 mL) 
No data 
available 
Cmax unchanged AUC 
unchanged 
The bioavailability of methylphenidate was not 
altered by sprinkling their contents onto a small 






60 mg 2 tablespoons applesauce 
overnight fast 
—4 h post 
dose 
Cmax unchanged AUC 
unchanged 
The bioavailability when sprinkled onto 
applesauce was similar to that of the intact 







1 tablespoon of yogurt 
1 tablespoon applesauce 
5mL infant formula 
overnight fast 
—4 h post 
dose 
Cmax unchanged AUC 
unchanged 
The bioavailability of rabeprazole granules was 
similar for all food stuffs evaluated 
[97] 
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Table 2. Cont. 
Drug Formulation Dose Food/Meal 
Timing of 
Dose 







High fat breakfast and 
227 mL of whole milk, 
ingested within a  
20 min period 
overnight fast 
—4 h post dose 
Cmax increased 
AUC unchanged 
The suspension formulation may be 
administered without regard to meals, 
increasing the convenience of once-daily dosing 
regimens 
[98] 




—4 h post dose 
Tmax prolonged  
Cmax reduced 
AUC unchanged 
Administer the dispersible tablet to each patient 
on a consistent basis either with or without food. 
[99] 
Glycopyrrolate 
oral solution (1 
mg/5mL) 
2 mg FDA High fat breakfast 
overnight fast 
—4 h post dose 
Cmax reduced 
AUC reduced 
Administer at least one hour before or after 
meals 
[100] 
Ibuprofen chewable tablets 200 mg 
Standardised breakfast 
plus 240 mL whole 
milk total calorie 
content = 650 calories 
overnight fast 
—4 h post dose 
Tmax prolonged 
Cmax reduced 














Recommended that patients take nelfinavir with 
a meal or snack 
[102] 
Nitazoxanide 
Suspension (25 mL 
of 100 mg/5 mL) 
500 mg 
High fat high calorie 
standardised breakfast 
and 240 mL whole milk 
overnight fast 







Suspension (42 mL 
of 24 mg/mL ) 
1008 mg 
Light calorie low fat 
breakfast 
meal 2.5 h prior 
to dosing 
(semi-fed state) 
Tmax prolonged Cmax 
unchangedAUC 
unchanged 
Food had a significant effect on the early 
exposure and onset of therapeutic level of 
paracetamol from the paediatric suspension 
[88] 
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Table 2. Cont. 
Drug Formulation Dose Food/Meal Timing of Dose 
Change in 
Parameter 
Remarks from Reference Reference 
Ritonavir oral solution 600 mg 
514 KCal; 9% fat, 12% 









oral suspension  
(40 mg/mL) 
400 mg High fat meal 
overnight fast— 




The rufinamide suspension is bioequivalent to 
the approved tablets 
[105] 
Sertraline HCl oral solution 100 mg Standardised breakfast 
overnight fast— 
4 h post dose 
Cmax unchanged 
AUC unchanged 
The pharmacokinetics of the sertraline oral 




oral solution (20 mL 
5mg/mL) 
100 mg 
High fat low calorie 
meal 
overnight fast— 
4 h post dose 
Tmax prolonged  
Cmax unchanged 
AUC unchanged 
A high-fat, high-calorie meal delays absorption 
of liquid topiramate without changing overall 




oral solution  
100 mg/mL (co 
administered with 
200 mg ritonavir) 
500 mg 
of   
Cmax reduced slightly 
AUC unchanged 
Oral solution can be administered to patients 
either with or without food. The current label 
recommends the tipranavir capsules be taken 
with food. 
[108] 
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The data presented shows a clear division into studies conducted that measure the effect of mixing 
medicines with the recommended food for administration (e.g., applesauce, yogurt infant formula) and 
those undertaken to understand a broader food effect. Supporting studies that measure the degradation 
of drugs in soft food to predict any ex vivo impact of food manipulation on drug stability have been 
conducted (e.g., [109]) although these are outside the scope of this review. 
As expected, all studies conducted using the recommended food for administration showed no 
significant change in bioavailability compared to the fasted state. However, the extrapolation of these 
studies into paediatric patients may be more complex than anticipated; particularly when considering 
the volume of food administered: a tablespoon in all studies [92–97] followed by 120–240 mL (median  
180 mL) of water which may not be a representative ratio in younger children. A reduced volume of 
both food and drink may have consequences on absorption resulting in a difference in the pharmacokinetic 
profile compared to fasted administration. 
It may also be necessary to consider the nature of the food utilised in common practice as the 
recommended food (e.g., applesauce) may be substituted for yogurt, jam or other foodstuffs resulting 
in a different pharmacokinetic profile [2]. The impact of a change in diet on pharmacokinetics has 
previously been reported; for example milk appeared to have a greater effect on 6-mercaptopurine 
compared to fruit juice [60]. 
The data in Table 2 shows that a standardised breakfast was used in most studies where a broader 
food effect was investigated. Of these 12 food effect studies, three demonstrated no pharmacokinetic 
impact of food and nine showed a clear impact with food. Where a food effect was reported this was 
managed by appropriate patient information labelling, for example, Kovarik et al., (2003) [99] 
compared the pharmacokinetic profile of everolimus as conventional IR tablets and a dispersible 
paediatric formulation in adults, as well as the effect of food on the absorption of the paediatric 
formulation. The result showed that the Cmax was halved in the presence of food yet the AUC 
remained the same therefore providing that the patient is consistent in how they take the drug their 
therapy is not compromised [99]. Other drugs have a therapeutic index more closely linked to the 
Cmax and in such cases the food effect may be more significant and require additional management. 
7. Predicting a Food Effect 
The effect of food on the pharmacokinetic profile of a drug is a significant concern during drug 
development and within subsequent clinical practice. A system that enables prediction of a food effect 
during development would have many benefits. However, it is recognised that such a model is 
complex due to the concurrent ongoing chemical and physiological variables associated with the 
postprandial changes in the gastrointestinal tract. This section highlights existing methods used to 
predict food effects for adult populations and explores their extrapolation into paediatric populations. 
7.1. Theoretical Models 
Previous studies [110] have linked physicochemical properties of drugs to the likelihood of a food 
effect in adult populations. Typical drug physicochemical properties included the dose:solubility ratio 
and drug lipophilicity which are the foundations of the biopharmaceutical classification system [111]. 
Key differences in paediatric patients’ physiology and anatomy as well as dose adjustments are likely 
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to result in differences in solubility values used in prediction of a food effect in adults. Therefore it is 
likely that these methods may not be appropriate in the prediction of food effects in paediatric patients. 
Typically intestinal concentrations and the dose:solubility ratio are likely to be higher in the youngest 
paediatric patients due to the lower volumes of intestinal fluids; resulting in a greater likelihood of a 
food effect for poorly soluble drugs. 
7.2. Physical Models 
7.2.1. Solubility/Dissolution Testing 
Alternative methods used to predict food effects include in vitro dissolution testing where the 
dissolution media is representative of adult fed gastrointestinal fluids. Fed state simulated intestinal 
media (FeSSIF) was developed to mimic intestinal fluid in the fed state and is currently the media of 
choice in predicting fed effects in adults [112]. Previous attempts to simulate typical postprandial 
gastric conditions include homogenised meals including the FDA standard breakfast, emulsions and 
complete nutrition products [113]. The current most appropriate simulated fluids that mimic the fed 
conditions within the stomach (in adults) are milk and Ensure® Plus (Ensure Plus® is a complete 
nutrition product) [12]. Both standardized homogenized cows’ milk with a fat content of 3.5% (whole 
milk) and Ensure® Plus have a similar composition to the FDA standard breakfast meal with respect to 
the ratio of carbohydrate/fat/protein [15]. Obviously milk has benefits in terms of simulating the 
gastric contents in neonates and young infants. 
The viscosity of the standard FDA breakfast was measured by Klein et al., (2004); this was greater 
than both milk, Ensure and Ensure plus® (nutrition drinks). In order to attain a viscosity similar to that 
of a solid meal a thickening agent was required to be added to the liquid media to appropriately mimic 
the physical properties of the fed state [15]. However, none of these media reflects all parameters that 
are important for determining food effects on drug release in the stomach (specifically in terms of  
pH changes and pepsin concentration). 
Dissolution testing using FeSSIF has previously shown good correlation to adult in vivo data, 
particularly for poorly soluble drugs (e.g., [114]). A technique that combined dissolution apparatus 
with a caco-2 monolayer to measure drug permeation was reported by Kataoka et al., (2006) [115]. 
This technique has provided in vitro data that correlated well to in vivo data for several drugs 
administered in the fed state. Other dynamic dissolution models that mimic the gastrointestinal tract in 
the fed state include TNO testing [116] and the dynamic gastric model [117]. A bespoke dynamic 
dissolution apparatus mimicking the conditions in the upper gastrointestinal tract of neonates, infants 
and toddlers has been reported where food effects were evaluated in vitro [118]. However, 
extrapolation of biorelevant dissolution testing to provide correlations to in vivo paediatric fed state 
data is yet to be reported. 
7.3. In Silico Models 
Physiologically based pharmacokinetic models have become a widely used tool for predicting food 
effects and simulating plasma profiles of drugs, particularly poorly soluble drugs. Typically these 
models rely on input parameters that include the solubility of the drug in both fasted and fed media as 
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well as dissolution data from FeSSIF media. However, their advantage over simple dissolution or 
solubility testing lies in the incorporation of permeability data and can allow the pattern of intestinal 
transit to be altered to match the fed state in adults. This methodology can be used to generate in vivo 
in silico relationships to better understand and predict food effects [119]. Although several 
physiologically relevant paediatric pharmacokinetic models are available (e.g., SimCYP, Gastroplus) 
there is no data on prediction of food effects within paediatric populations using these models [120]. 
8. Conclusions 
Although the practice of mixing medicines with food to enhance acceptability to children is known 
to be widespread, the consequences are unexplored for many drugs. 
The lack of regulation surrounding fed studies conducted in children and young people leads to 
great variability in the design and conduct of such studies. This leads to confusion as to what foods are 
and are not acceptable for co-administration with a particular medicine with potentially serious 
consequences. Additional research is required to better understand which foods should be used to 
provide a worst-case scenario equivalent to the FDA breakfast that is used in adult fed effect studies. 
Fed effects observed in adult populations are not necessarily observed within a paediatric 
population and vice versa; therefore extrapolation of such effects needs to be undertaken with caution. 
The restricted availability of pharmacokinetic data from fed-paediatric clinical studies currently limits 
the development of relevant and validated in vitro and in silico tests to better predict food effects 
within paediatric populations. There is insufficient evidence to justify extrapolation of existing 
methods used to predict food effects in adults directly to paediatric populations. 
In conclusion, the impact of food on the pharmacokinetics in children cannot be predicted using 
existing methods. Additional research is required to understand the physiological and anatomical 
factors that can influence the absorption of a drug in paediatric populations. Furthermore, food effect 
studies should be undertaken in paediatric patients where a known food effect occurs in adults. 
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